-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, VGbjGXm17/AVBkvFVrAOtWHhVD5SigIFH/LmiPTJHNKnTbbBUfKpG5rjlmbmuVBc DnAP+rrCPuU4AOsfKi41MQ== 0001144204-08-034507.txt : 20080611 0001144204-08-034507.hdr.sgml : 20080611 20080610175629 ACCESSION NUMBER: 0001144204-08-034507 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20080611 DATE AS OF CHANGE: 20080610 GROUP MEMBERS: FELIX J. BAKER SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: GENOMIC HEALTH INC CENTRAL INDEX KEY: 0001131324 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 770552594 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-81275 FILM NUMBER: 08891644 BUSINESS ADDRESS: STREET 1: 301 PENOBSCOT DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 650-556-9300 MAIL ADDRESS: STREET 1: 301 PENOBSCOT DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BAKER JULIAN CENTRAL INDEX KEY: 0001087939 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: TISCH FAMILY INTERESTS STREET 2: 667 MADISON AVENUE CITY: NEW YORK STATE: NY ZIP: 10021 BUSINESS PHONE: 212-339-5600 MAIL ADDRESS: STREET 1: BAKER BROTHERS ADVISORS STREET 2: 667 MADISON AVENUE CITY: NEW YORK STATE: NY ZIP: 10021 SC 13D/A 1 v116991_sc13da.htm Unassociated Document
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
SCHEDULE 13D
Under the Securities Exchange Act of 1934
 
(Amendment No. 3)
 
Genomic Health, Inc
(Name of Issuer)
     
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
     
 
37244C101
 
 
(CUSIP Number)
 
     
Leo Kirby
667 Madison Avenue, 17th Floor
New York, NY 10065
(212) 339-5633
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
     
 
June 9, 2008
 
 
(Date of Event which Requires Filing of this Statement)
 
     

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. X
 
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.
 
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
 
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
 
Page 1of 7 Pages

 
      
     
CUSIP No. 37244C101
 
 
     
1
NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
 
     
 
Julian C. Baker
 
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
 
   
(a) o
   
(b) o
3
SEC USE ONLY
 
     
     
4
SOURCE OF FUNDS (See Instructions)
 
     
 
WC
 
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
 
     
   
o
6
CITIZENSHIP OR PLACE OF ORGANIZATION
 
     
 
United States
 
 
7
SOLE VOTING POWER
 
   
NUMBER OF
  
16,500
SHARES
8
SHARED VOTING POWER
BENEFICIALLY
 
 
OWNED BY
  
5,374,284
EACH
9
SOLE DISPOSITIVE POWER
REPORTING
   
PERSON
  
16,500
WITH
10
SHARED DISPOSITIVE POWER
 
   
    
5,374,284
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
     
 
5,390,784
 
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
 
     
      
o
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
 
     
 
19.1%
 
14
TYPE OF REPORTING PERSON (See Instructions)
 
     
 
IN
 
 
Page 2of 7 Pages

 
      
     
CUSIP No. 37244C101
 
 
     
1
NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS
 
     
 
Felix J. Baker
 
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
 
   
(a) o
   
(b) o
3
SEC USE ONLY
 
     
     
4
SOURCE OF FUNDS (See Instructions)
 
     
 
WC
 
5
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)
 
     
   
o
6
CITIZENSHIP OR PLACE OF ORGANIZATION
 
     
 
United States
 
 
7
SOLE VOTING POWER
 
   
NUMBER OF
  
0
SHARES
8
SHARED VOTING POWER
BENEFICIALLY
 
 
OWNED BY
  
5,374,284
EACH
9
SOLE DISPOSITIVE POWER
REPORTING
   
PERSON
  
0
WITH
10
SHARED DISPOSITIVE POWER
 
   
    
5,374,284
11
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
     
 
5,374,284
 
12
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)
 
     
      
o
13
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
 
     
 
19.0%
 
14
TYPE OF REPORTING PERSON (See Instructions)
 
     
 
IN
 
 
Page 3of 7 Pages

 
This Amendment No. 3 to Schedule 13D is being filed by Julian C. Baker and Felix J. Baker (the “Reporting Persons”) to supplement the statements on Schedule 13D previously filed by them, as heretofore amended. Except as supplemented herein, such statements, as heretofore amended and supplemented, remain in full force and effect.
 
Item 5. Interest in Securities of the Issuer.
 
Set forth below is the aggregate number of shares of Common Stock held, including shares that maybe acquired upon exercise of Options as of the date hereof by each of the following, together with the percentage of outstanding shares of Common Stock that such number represents based upon 28,245,371 shares outstanding, as reported on the company’s SEC Form 10Q filed on May 12, 2008. Such percentage figures are calculated on the basis that the shares of Options owned by the Reporting Persons are deemed exercised for shares of Common Stock but other outstanding shares of Options are not deemed converted or exercised.
 
Name
 
Number of
Shares
 
Percent of Class
Outstanding
 
           
Baker Bros. Investments, L.P.
 
 173,897
 
   0.6%
 
Baker Bros. Investments II, L.P.
 
 20,095
 
   0.1%
 
Baker Biotech Fund I, L.P.
 
 1,226,119
 
   4.3%
 
Baker Brothers Life Sciences, L.P.
 
 3,492,192
 
  12.4%
 
14159, L.P.
 
 94,325
 
   0.3%
 
FBB Associates
 
 173,897
 
   0.6%
 
Baker/Tisch Investments, L.P.
 
 193,759
 
   0.7%
 
Julian C. Baker
 
 16,500
 
   0.1%
 
Total
 
   
5,390,784
   
19.1%
 
 
By virtue of their ownership of entities that have the power to control the investment decisions of the limited partnerships listed in the table above, Julian C. Baker and Felix J. Baker may each be deemed to be beneficial owners of shares owned by such entities and may be deemed to have shared power to vote or direct the vote of and shared power to dispose or direct the disposition of such securities. Julian C. Baker and Felix J. Baker are also the sole partners of FBB Associates, a general partnership, and as such may be deemed to be beneficial owners of shares owned by FBB Associates and may be deemed to have shared power to vote or direct the vote and dispose or direct the disposition of those shares. Because of certain relationships with other security holders of the Issuer, the Reporting Persons are filing solely for informational purposes as if they were a member of a group of such shareholders.  However, the Reporting Persons disclaim that they and any other person or persons, in fact constitute a “group” for the purposes of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, or Rule 13d-5 thereunder or that they are the beneficial owners of securities owned by any such other persons, and each of them disclaim beneficial ownership of securities reported herein except to the extent of their pecuniary interest, if any therein.
 
Page 4of 7 Pages

 
Julian C. Baker is a Director of the Company.
 
The following transactions in Common Stock were effected by the entities noted below during the sixty days preceding the filing of this statement. None of the reporting Persons has effected any other transactions in Common Stock during this period.
 
 
 
 
 
Number of
 
 
 
 
 
Name
 
Date
 
Shares
 
Transaction
 
Price / Share
 
                   
Baker Biotech Fund I, L.P.
   
6/5/2008
   
56
   
Purchase
   
19.5000
 
Baker Brothers Life Sciences, L.P.
   
6/5/2008
   
236
   
Purchase
   
19.5000
 
14159, L.P.
   
6/5/2008
   
8
   
Purchase
   
19.5000
 
Baker Biotech Fund I, L.P.
   
6/5/2008
   
22,883
   
Purchase
   
19.6083
 
Baker Brothers Life Sciences, L.P.
   
6/5/2008
   
96,627
   
Purchase
   
19.6083
 
14159, L.P.
   
6/5/2008
   
3,100
   
Purchase
   
19.6083
 
Baker Biotech Fund I, L.P.
   
6/6/2008
   
1,103
   
Purchase
   
20.0101
 
Baker Brothers Life Sciences, L.P.
   
6/6/2008
   
4,655
   
Purchase
   
20.0101
 
14159, L.P.
   
6/6/2008
   
149
   
Purchase
   
20.0101
 
Baker Biotech Fund I, L.P.
   
6/6/2008
   
36,554
   
Purchase
   
20.2096
 
Baker Brothers Life Sciences, L.P.
   
6/6/2008
   
154,355
   
Purchase
   
20.2096
 
14159, L.P.
   
6/6/2008
   
4,953
   
Purchase
   
20.2096
 
Baker Biotech Fund I, L.P.
   
6/9/2008
   
8,271
   
Purchase
   
19.6655
 
Baker Brothers Life Sciences, L.P.
   
6/9/2008
   
34,926
   
Purchase
   
19.6655
 
14159, L.P.
   
6/9/2008
   
1,121
   
Purchase
   
19.6655
 
Baker Biotech Fund I, L.P.
   
6/9/2008
   
6,849
   
Purchase
   
19.6566
 
Baker Brothers Life Sciences, L.P.
   
6/9/2008
   
28,923
   
Purchase
   
19.6566
 
14159, L.P.
   
6/9/2008
   
928
   
Purchase
   
19.6566
 
Baker Biotech Fund I, L.P.
   
6/9/2008
   
168
   
Purchase
   
19.6133
 
Baker Brothers Life Sciences, L.P.
   
6/9/2008
   
709
   
Purchase
   
19.6133
 
14159, L.P.
   
6/9/2008
   
23
   
Purchase
   
19.6133
 
Baker Biotech Fund I, L.P.
   
6/9/2008
   
131
   
Purchase
   
19.6400
 
Baker Brothers Life Sciences, L.P.
   
6/9/2008
   
552
   
Purchase
   
19.6400
 
14159, L.P.
   
6/9/2008
   
17
   
Purchase
   
19.6400
 
 
Item 6.  Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.
 
Except as reported herein, neither of the Reporting Persons has any express contracts, arrangements or understandings with any other Reporting Person with respect to the securities of the Company. Except as set forth in Item 7 below, none of the Reporting Persons has any contracts, arrangements, understandings or relationships with the Company.
 
Item 7.  Material to Be Filed as Exhibits.
 
Exhibit 1.    Agreement regarding the joint filing of this statement.

Page 5of 7 Pages

 
SIGNATURE
 
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
 
 June 10, 2008    
   
 
 
 
 
 
 
  By:   /s/ Julian C. Baker
 
Julian C. Baker
   
     
 
 
 
 
 
 
  By:   /s/ Felix J. Baker
 
Felix J. Baker
   


Page 6of 7 Pages

EX-1 2 v116991_ex1.htm Unassociated Document
EXHIBIT 1

AGREEMENT
 
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13D relating to the Common Stock, $0.0001 par value, of Genomic Health, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them.
 
 
 June 10, 2008    
   
 
 
 
 
 
 
  By:   /s/ Julian C. Baker
 
Julian C. Baker
   
     
 
 
 
 
 
 
  By:   /s/ Felix J. Baker
 
Felix J. Baker
   

Page 8of 7 Pages

-----END PRIVACY-ENHANCED MESSAGE-----